Spinal Muscular Atrophy Movement Defects Cause Possibly Found Discovery Of Possible In cause of movement defects in spinal muscular atrophy identified Scientists find possible

Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA) ELK GROVE VILLAGE, Ill. -- Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate ... Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy . Repligen Announces Favorable Results from Phase 1 Clinical Trial of Experimental Treatment for Spinal Muscular Atrophy TUCSON, Ariz., April 25, 2012 /PRNewswire-USNewswire/ -- Repligen Corp., in Waltham, Mass., announced today that its experimental drug RG3039, designed to treat spinal muscular atrophy (SMA), was safe and well-tolerated in a phase 1 clinical trial. In addition, data suggested that the drug reached and acted on its biological target, an enzyme called DcpS. Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA). New home construction to support SMA research DELANO, MN – More than anything, Jeff Martineau wants to help his 9-year-old daughter, Isabella, who was born with spinal muscular atrophy (SMA). Spinal Muscular Atrophy - Movement Defects Cause Possibly Found According to a study published in the April 11 issue of The Journal of Neuroscience, researchers have found that an abnormally low level of survival motor neuron protein (SMN), in certain nerve cells, is associated with mobility problems that characterize spinal muscular atrophy (SMA) - a deadly childhood disorder. SMA is a genetic disorder in which motor neurons do not produce enough SMN. Motor ... The Spinal Muscular Atrophy Foundation Announces a Biomarker Panel to Guide SMA Therapeutic Development NEW YORK, April 3, 2012 /PRNewswire/ -- The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM's Multi-Analyte Profiling (MAP) technology ... Press Release Repligen Corporation (NASDAQ:RGEN) today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA). SMA is a inherited neurodegenerative disease in which symptoms of progressive damage to motor neurons including loss of muscle function ... Repligen sees positive results from SMA trial Repligen Corp. (Nasdaq: RGEN) of Waltham said its Phase 1 study of RG3039, a small molecule drug candidate for treating spinal muscular atrophy (SMA), yielded positive results. Possible cause of movement defects in spinal muscular atrophy identified An abnormally low level of a protein in certain nerve cells is linked to movement problems that characterize the deadly childhood disorder spinal muscular atrophy, new research in animals suggests.
Key Words: spinal muscular atrophy

References:
http://feedproxy.google.com/~r/mnt/healthnews/~3/dYXKxXDeM-E/244147.php
http://feedproxy.google.com/~r/mnt/healthnews/~3/xz46IzhmAd4/244036.php
http://feeds.sciencedaily.com/~r/sciencedaily/~3/RHeUNdenpZ4/120411102723.htm
http://www.eurekalert.org/pub_releases/2012-04/osu-sfp041012.php
http://pixelhat.net/